Drug maker Alvotech announced this week that it has raised $300 million, through a private bond offering, that it will used to continue its growth, refinance debt, and further develop its biosimilar pipeline.
Drug maker Alvotech announced this week that it has raised $300 million, through a private bond offering, that it will used to continue its growth, refinance debt, and further develop its biosimilar pipeline.
In a statement, Alvotech’s founder, Robert Wessman, said that the cash infusion would help the company to further its biosimilar development and fund its clinical studies, “the results of which bring significant potential for healthcare providers around the world to drive healthcare savings and expand patient access to high-quality biosimilars.”
The Iceland-headquartered biosimilar developer, founded in 2013 by Wessman, has 6 monoclonal antibodies in its pipeline. To date, the company has not disclosed the specific biosimilars that it is developing, saying only that the products target cancer, autoimmune diseases, inflammatory conditions, and other disease states. Alvotech has previously said that it anticipates the first of its products to be brought to market by 2020.
Last month, Fuji Pharma announced that it had acquired a 4.2% stake—worth approximately $50 million—in Alvotech. That acquisition came shortly on the heels of an announcement that the 2 companies would partner to commercialize Alvotech’s entire pipeline of biosimilars in the Japanese market.
Through the partnership agreement, Alvotech will be responsible for the development and supply of biosimilars, while Fuji Pharma will be responsible for filing the products with Japan’s regulatory agency, as well as the commercialization of the approved biosimilars.
Additionally, in 2018, Alvotech forged an agreement with Changchung High & New Technology Industries Group to enable the development, manufacture, and commercialization of biosimilars in China.
In order to keep pace with its anticipated supply needs, Alvotech recently built a new state-of-the-art biopharmaceutical facility in Reykjavik, Iceland, which was granted licensure by the Icelandic Medicines Agency, together with the Irish Health Products Regulatory Authority, in 2018. Additionally, the company owns manufacturing plants in Germany and Switzerland.
Other key shareholders in Alvotech include controlling shareholder Aztiq Pharma AB, led by Wessman, and generic pharmaceutical company Alvogen.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.